Combination of peptide YY3-36 with GLP-17-36 amide causes an increase in first-phase insulin secretion after IV glucose

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages E2317-E2324

  Tan, Tricia M ^a   Salem, Victoria ^a   Troke, Rachel C ^a   Alsafi, Ali ^a   Field, Benjamin C T ^a   De Silva, Akila ^a   Misra, Shivani ^a   Baynes, Kevin C R ^a   Donaldson, Mandy ^a   Minnion, James ^a   Ghatei, Mohammad A ^a   Godsland, Ian F ^b   Bloom, Stephen R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; PEPTIDE YY [3-36]; PLACEBO; GLUCAGON LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; GLUCOSE BLOOD LEVEL; INSULIN; PEPTIDE FRAGMENT; PEPTIDE YY;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE TRACT PARAMETERS; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN SENSITIVITY INDEX; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MIDDLE AGED; MONOTHERAPY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; YOUNG ADULT; BLOOD; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INSULIN RESISTANCE;

ADULT; BLOOD GLUCOSE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PEPTIDE FRAGMENTS; PEPTIDE YY; YOUNG ADULT;

EID: 84910001748     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2143     Document Type: Article

References (37)

1. WHO Consultation. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894: i-xii, 1-253.
2. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007; 357: 753-761.
3. Sjöström L. Bariatric surgery and reduction in morbidity and mortality: Experiences from the SOS study. Int J Obes (Lond). 2008; 32 Suppl 7: S93-S97.
4. Sjöström L, Gummesson A, Sjöström CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): A prospective, controlled intervention trial. Lancet Oncol. 2009; 10: 653-662.
5. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007; 357: 741-752.
6. Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: Mechanisms and 2 year outcomes. Ann Surg. 2010; 252: 966-971.
7. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006; 243: 108-114.
8. Bueter M, Miras AD, Chichger H, et al. Alterations of sucrose preference after Roux-en-Y gastric bypass. Physiol Behav. 2011; 104: 709-721.
9. 3-36 cause nausea, but no additional reduction in food intake. Ann Clin Biochem. 2008; 45: 93-95.
10. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet. 2009; 374: 1606-1616.
11. De Silva A, Salem V, Long CJ, et al. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab. 2011; 14: 700-706.
12. 3-36 and glucagon- like peptide-17-36 inhibit food intake additively. Endocrinology. 2005; 146: 5120-5127.
13. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet. 1987; 2: 1300-1304.
14. Schwetz TA, Ustione A, Piston DW. Neuropeptide Y and somatostatin inhibit insulin secretion through different mechanisms. Am J Physiol Endocrinol Metab. 2013; 304: E211-E221.
15. Wang ZL, Bennet WM, Wang RM, Ghatei MA, Bloom SR. Evidence of a paracrine role of neuropeptide-Y in the regulation of insulin release from pancreatic islets of normal and dexamethasonetreated rats. Endocrinology. 1994; 135: 200-206.
16. Skoglund G, Gross R, Ahrén B, Loubatières-MarianiMM.Different mechanisms are involved in neuropeptide Y-induced pancreatic vasoconstriction and inhibition of insulin secretion. Eur J Pharmacol. 1993; 236: 69-74.
17. Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad SciUSA. 1998; 95: 15659-15664.
18. Szecówka J, Tatemoto K, Rajamäki G, Efendic S. Effects of PYY and PP on endocrine pancreas. Acta Physiol Scand. 1983; 119: 123-126.
19. Böttcher G, Ahrén B, Lundquist I, Sundler F. Peptide YY: Intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas. 1989; 4: 282-288.
20. Nieuwenhuizen AG, Karlsson S, Fridolf T, Ahrén B. Mechanisms underlying the insulinostatic effect of peptide YY in mouse pancreatic islets. Diabetologia. 1994; 37: 871-878.
21. Greeley GH, Jr, Lluis F, Gomez G, Ishizuka J, Holland B, Thompson JC. Peptide YY antagonizes beta-adrenergic-stimulated release of insulin in dogs. Am J Physiol. 1988; 254: E513-E517.
22. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab. 2007; 292: E1062-E1068.
23. Malmström RE, Lundberg JO, Weitzberg E. Autoinhibitory function of the sympathetic prejunctional neuropeptide Y Y (2) receptor evidenced by BIIE0246. Eur J Pharmacol. 2002; 439: 113-119.
24. van den Hoek AM, Heijboer AC, Corssmit EP, et al. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes. 2004; 53: 1949-1952.
25. Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology. 2001; 142: 4244-4250.
26. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003; 52: 380-386.
27. Kraegen EW, Lazarus L, Meler H, Campbell L, Chia YO. Carrier solutions for low-level intravenous insulin infusion. BMJ. 1975; 3: 464-466.
28. Pacini G, Mari A. 2007. Assessment of insulin sensitivity from steady-state and dynamic tests. In: Roden M, ed. Clinical diabetes research: Methods and techniques. Chichester, England: John Wiley, Sons; 27-41.
29. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000; 24: 38-48.
30. Adrian TE, Savage AP, Sagor GR, et al. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology. 1985; 89: 494-499.
31. Ghatei MA, Uttenthal LO, Bryant MG, Christofides ND, Moody AJ, Bloom SR. Molecular forms of glucagon-like immunoreactivity in porcine intestine and pancreas. Endocrinology. 1983; 112: 917-923.
32. Kahn SE, Carr DB, Faulenbach MV, Utzschneider KM. An examination of beta-cell function measures and their potential use for estimating beta-cell mass. Diab Obes Metab. 2008; 10 Suppl 4: 63-76.
33. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990; 300: 230-235.
34. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979; 236: E667-E677.
35. Godsland IF, Agbaje OF, Hovorka R. Evaluation of nonlinear regression approaches to estimation of insulin sensitivity by the minimal model with reference to Bayesian hierarchical analysis. Am J Physiol Endocrinol Metab. 2006; 291: E167-E174.
36. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993; 42: 1663-1672.
37. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes. 2002; 51 Suppl. 1: S117-S121.